Medicare denied my GLP-1 Bridge application because of sleep apnea. What now?

Because CMS treats moderate-to-severe obstructive sleep apnea (OSA) as a Part D condition, not a Bridge condition. Its guidance for prescribers says type 2 diabetes, moderate to severe OSA and MASH "are eligible for Part D coverage", that a beneficiary with a GLP-1 prescription for a Part D-covered use "should continue to obtain their GLP-1 through their Part D plan", and that the Bridge supplies GLP-1s only "when prescribed for a weight management indication" (CMS). Medicare.gov lists moderate-to-severe sleep apnea among the reasons a person is not eligible, because "your Medicare drug plan should cover GLP-1 medications to treat these conditions" (Medicare.gov).

What people in Zepbound support groups report. Members of Facebook groups for Zepbound users have been posting since the Bridge opened that their applications came back refused, and that the reason they were given was sleep apnea in their medical records. These are individual accounts we have not verified.

What CMS has and has not said about how this is checked. CMS says the Bridge "may independently verify" what a prescriber enters on the prior authorization form "by checking Medicare data"; the example it gives is type 2 diabetes. CMS does not publish how it uses sleep apnea diagnoses in that check, so we cannot tell you why a particular application was refused. Two more rules from the same CMS page matter: there is no appeals process under the Bridge, and a prescriber may resubmit the form "if they initially entered incorrect information or have updated or additional information to include." Call 1-800-MEDICARE (1-800-633-4227) to ask about the status of your own request.

Because it can point you to a route with no end date. On December 20, 2024 the FDA approved Zepbound "for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity" (FDA), the first drug approved for OSA. The law that keeps Part D from covering weight-loss drugs does not stop a plan covering a drug for another FDA-approved use. In January 2025 CMS said that current Part D coverage rules apply to Zepbound's sleep apnea use, meaning plans can cover it for OSA and may require prior authorization (CMS statement, reported by CNBC). CMS's current guidance to Part D plans lists moderate to severe OSA as an indication "eligible for Part D coverage" (CMS, information for Part D plans).

Two limits. "Can cover" is not "must cover": each Part D plan decides whether Zepbound is on its drug list and at what tier, which is why the plan you pick at Open Enrollment matters. And the sleep apnea route is Zepbound only; Wegovy and Foundayo are not approved for OSA. KFF notes that people who get a GLP-1 through Part D for sleep apnea pay their plan's cost-sharing "even if it's more than" the Bridge copay (KFF). Unlike the Bridge, which ends December 31, 2027, Part D coverage for an approved use carries on from year to year.

Three things: check which Part D plans in your ZIP code cover Zepbound and at what cost, have your prescriber request Zepbound from your plan for sleep apnea rather than weight loss, and be accurate about how severe your sleep apnea is. Open Enrollment closes December 7.

1. Price Zepbound in the Plan Finder (October 15 to December 7). Medicare Open Enrollment runs October 15 to December 7, and a plan you choose then starts January 1. On the Medicare Plan Finder, enter your ZIP code, add Zepbound to your drug list along with every other drug you take, and compare plans: for each one it shows whether Zepbound is covered, its tier, restrictions such as prior authorization, and your estimated yearly cost. Check your current plan too; it may already cover Zepbound. Changing plans affects all your drugs and, for Medicare Advantage, your doctors, so call 1-800-MEDICARE or your State Health Insurance Assistance Program (SHIP) before you switch.
2. Ask your prescriber for a Part D prior authorization for sleep apnea, not weight loss. The request goes to your Part D plan, not to the Bridge. It should name obstructive sleep apnea as the diagnosis and attach the sleep study report showing your apnea-hypopnea index (AHI, the number of breathing pauses and shallow breaths per hour), plus your current BMI with height and weight. A request written as weight loss is the one Part D is barred from covering. If Zepbound is not on your plan's formulary, ask for a formulary exception: CMS says people with moderate-to-severe OSA are not eligible for the Bridge "regardless of whether their current Part D plan covers a GLP-1 drug", and that plans "must continue to follow their existing formulary exception processes" for these requests (CMS), so a plan cannot send you back to the Bridge. If the plan refuses, the regular Part D coverage determination and appeal steps apply; the Bridge's no-appeals rule does not.
3. If your OSA is mild, say so and do not stretch it. Both the Zepbound approval and CMS's Part D list cover moderate to severe OSA only. The label's sleep apnea trials enrolled adults with an AHI of 15 or more and a BMI of 30 or more (Zepbound label). With mild OSA the Part D sleep apnea route does not fit. CMS's Bridge pages name only moderate-to-severe OSA among the conditions that send people to Part D, tell prescribers to use their clinical judgment on whether that diagnosis applies, and allow a resubmission with additional information. Ask your prescriber whether to resubmit the Bridge form with the sleep study attached. CMS has not said how it decides such cases, and neither will we.

The Bridge is cheaper per month and covers more drugs, but ends December 31, 2027 and has no appeals. The Part D sleep apnea route covers Zepbound only, costs whatever your plan charges, and has no end date.

The Bridge rules in full, with a four-question eligibility check: who qualifies for the Medicare GLP-1 Bridge.

Then you are paying cash, and the question is which cash route costs least for you. Manufacturer savings cards are not an option: both the Zepbound and Wegovy cards exclude anyone enrolled in Medicare or another government program (card terms: Zepbound, Wegovy). The manufacturers' self-pay prices are different: Novo Nordisk says government-insured patients may use its self-pay pharmacy if they pay cash (NovoCare), and LillyDirect's self-pay terms require only that you pay cash.

• Self-pay options for people on Medicare: LillyDirect, NovoCare and TrumpRx prices by dose, checked on the official pages.
• GLP-1 cost by route: every cash route with monthly price, yearly total and cost per pound lost.
• What to do when insurance won't cover Wegovy or Zepbound: denial types and how appeals work.
• Appeal letter builder: a Part D redetermination letter and a letter-of-medical-necessity draft for your prescriber.

Compounded semaglutide and tirzepatide cost less than the brands, have no FDA approval, and are not covered by the Bridge or Part D.

• Bridge exclusions, verification, no appeals, resubmission: CMS, Medicare GLP-1 Bridge: information for providers, read 2026-09-21.
• OSA as a Part D indication: CMS, Medicare GLP-1 Bridge: information for Part D plans, read 2026-09-21.
• Eligibility, covered drugs, dates, copay: Medicare.gov, Weight loss drugs, read 2026-09-21.
• Zepbound's sleep apnea approval and trial entry criteria: FDA, FDA approves first medication for obstructive sleep apnea (December 20, 2024); Zepbound prescribing information; SURMOUNT-OSA, NEJM 2024.
• Comparing plans: Medicare.gov, Medicare Plan Finder.
• Part D cost-sharing versus the Bridge copay: KFF, What Medicare's temporary program covering GLP-1s for obesity means for beneficiaries (March 2026).
• CMS on Part D coverage for sleep apnea (January 2025): CNBC, January 8, 2025.
• Savings card exclusion: Zepbound and Wegovy card terms.